Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Genital Neoplasms, Male

ClinicalTrials.gov lists 6,818 trials for Genital Neoplasms, Male or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 220.

MeSH D005834 Neoplasms Neoplasm C04 C12
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 840 Phase 1/2 Phase 1/2 413 Phase 2 Phase 2 1,565 Phase 2/3 Phase 2/3 81 Phase 3 Phase 3 550 Phase 4 Phase 4 124 Not applicable Not applicable 1,864 Observational Observational 1,351 Phase 1 Phase 1 840 Phase 1/2 Phase 1/2 413 Phase 2 Phase 2 1,565 Phase 2/3 Phase 2/3 81 Phase 3 Phase 3 550 Phase 4 Phase 4 124 Not applicable Not applicable 1,864 Observational Observational 1,351

Trials per phase (log scale)

2 more sections with rows

40 of the 6,818 trials are tagged with Genital Neoplasms, Male itself; the rest are tagged with a narrower condition beneath it.

Get the Genital Neoplasms, Male report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Genital Neoplasms, Male trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 13 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 392

1990: 5 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 1, Phase 1/2 1) 1991: 4 trials (Observational 1, Phase 2 1, Phase 1 2) 1992: 6 trials (Observational 1, Phase 3 3, Phase 2 2) 1993: 7 trials (Observational 5, Not applicable 1, Phase 2 1) 1994: 10 trials (Observational 1, Phase 3 5, Phase 1/2 3, Phase 1 1) 1995: 20 trials (Observational 3, Phase 3 9, Phase 2 3, Phase 1/2 1, Phase 1 4) 1996: 16 trials (Observational 2, Not applicable 1, Phase 3 6, Phase 2 6, Phase 1 1) 1997: 34 trials (Observational 1, Not applicable 7, Phase 3 6, Phase 2 10, Phase 1/2 2, Phase 1 8) 1998: 49 trials (Observational 5, Not applicable 2, Phase 3 11, Phase 2/3 1, Phase 2 17, Phase 1/2 3, Phase 1 10) 1999: 58 trials (Observational 3, Not applicable 3, Phase 3 16, Phase 2/3 1, Phase 2 18, Phase 1/2 5, Phase 1 12) 2000: 68 trials (Observational 3, Not applicable 1, Phase 3 11, Phase 2 32, Phase 1/2 6, Phase 1 15) 2001: 81 trials (Observational 5, Not applicable 6, Phase 4 1, Phase 3 12, Phase 2/3 2, Phase 2 36, Phase 1/2 6, Phase 1 13) 2002: 105 trials (Observational 12, Not applicable 12, Phase 4 6, Phase 3 12, Phase 2/3 3, Phase 2 43, Phase 1/2 7, Phase 1 10) 2003: 130 trials (Observational 13, Not applicable 19, Phase 4 8, Phase 3 22, Phase 2/3 1, Phase 2 47, Phase 1/2 7, Phase 1 13) 2004: 150 trials (Observational 24, Not applicable 14, Phase 4 5, Phase 3 17, Phase 2/3 2, Phase 2 59, Phase 1/2 12, Phase 1 17) 2005: 176 trials (Observational 24, Not applicable 31, Phase 4 4, Phase 3 24, Phase 2/3 3, Phase 2 53, Phase 1/2 15, Phase 1 22) 2006: 197 trials (Observational 25, Not applicable 29, Phase 4 6, Phase 3 22, Phase 2/3 7, Phase 2 60, Phase 1/2 19, Phase 1 29) 2007: 198 trials (Observational 30, Not applicable 34, Phase 4 4, Phase 3 22, Phase 2/3 1, Phase 2 70, Phase 1/2 7, Phase 1 30) 2008: 190 trials (Observational 36, Not applicable 36, Phase 4 2, Phase 3 18, Phase 2 59, Phase 1/2 13, Phase 1 26) 2009: 204 trials (Observational 34, Not applicable 47, Phase 4 3, Phase 3 27, Phase 2/3 3, Phase 2 50, Phase 1/2 13, Phase 1 27) 2010: 177 trials (Observational 36, Not applicable 38, Phase 4 2, Phase 3 13, Phase 2/3 2, Phase 2 45, Phase 1/2 17, Phase 1 24) 2011: 215 trials (Observational 43, Not applicable 54, Phase 4 7, Phase 3 17, Phase 2/3 2, Phase 2 56, Phase 1/2 8, Phase 1 28) 2012: 223 trials (Observational 35, Not applicable 64, Phase 4 6, Phase 3 17, Phase 2/3 4, Phase 2 59, Phase 1/2 12, Phase 1 26) 2013: 229 trials (Observational 48, Not applicable 64, Phase 4 3, Phase 3 13, Phase 2/3 2, Phase 2 63, Phase 1/2 14, Phase 1 22) 2014: 276 trials (Observational 56, Not applicable 87, Phase 4 4, Phase 3 18, Phase 2/3 1, Phase 2 64, Phase 1/2 10, Phase 1 36) 2015: 268 trials (Observational 74, Not applicable 85, Phase 4 6, Phase 3 14, Phase 2/3 1, Phase 2 43, Phase 1/2 13, Phase 1 32) 2016: 289 trials (Observational 64, Not applicable 87, Phase 4 6, Phase 3 16, Phase 2/3 6, Phase 2 56, Phase 1/2 13, Phase 1 41) 2017: 287 trials (Observational 67, Not applicable 95, Phase 4 6, Phase 3 13, Phase 2/3 1, Phase 2 63, Phase 1/2 13, Phase 1 29) 2018: 297 trials (Observational 54, Not applicable 106, Phase 4 2, Phase 3 13, Phase 2/3 7, Phase 2 68, Phase 1/2 19, Phase 1 28) 2019: 312 trials (Observational 71, Not applicable 95, Phase 4 7, Phase 3 14, Phase 2/3 6, Phase 2 64, Phase 1/2 16, Phase 1 39) 2020: 318 trials (Observational 82, Not applicable 95, Phase 4 1, Phase 3 25, Phase 2/3 6, Phase 2 50, Phase 1/2 18, Phase 1 41) 2021: 343 trials (Observational 76, Not applicable 114, Phase 4 3, Phase 3 21, Phase 2/3 6, Phase 2 63, Phase 1/2 17, Phase 1 43) 2022: 298 trials (Observational 73, Not applicable 121, Phase 4 3, Phase 3 16, Phase 2 40, Phase 1/2 15, Phase 1 30) 2023: 353 trials (Other 1, Observational 82, Not applicable 128, Phase 4 5, Phase 3 25, Phase 2/3 4, Phase 2 50, Phase 1/2 18, Phase 1 40) 2024: 392 trials (Observational 95, Not applicable 118, Phase 4 12, Phase 3 18, Phase 2/3 2, Phase 2 72, Phase 1/2 25, Phase 1 50) 2025: 357 trials (Observational 76, Not applicable 129, Phase 4 4, Phase 3 23, Phase 2/3 1, Phase 2 57, Phase 1/2 29, Phase 1 38)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 393
2025 357
2024 392
2023 353
2022 298
2021 343
2020 318
2019 312
2018 297
2017 287

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 440 trials starting in 2026 and about 400 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 853 trials still running at the 2026-10-09 snapshot; registered median of 35 months across 4,038 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Genital Neoplasms, Male trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 840
Phase 1/2 413
Phase 2 1,565
Phase 2/3 81
Phase 3 550
Phase 4 124
Not applicable 1,864
Observational 1,351
Expanded access 29
Unknown 1

How many Genital Neoplasms, Male trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 247
Recruiting 1,053
Enrolling by invitation 41
Active, not recruiting 544
Available 6

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Genital Neoplasms, Male trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 220
AstraZeneca 70
Novartis Pharmaceuticals 56
Bayer 49
Janssen Research & Development, LLC 48

Which drugs are being tested for Genital Neoplasms, Male? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Prednisone 214
Abiraterone 212
Enzalutamide 193
Bicalutamide 112
Apalutamide 93

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Docetetaxel 270
Lupron / Leuprolide acetate 120
Radiation Therapy 111
Goserelin Depot 94
Degarelix 80 mg / Degarelix 80 mg 91

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Genital Neoplasms, Male trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,432 192
Anaemia 1,143 151
Fatigue 948 169
Febrile neutropenia 854 112
Urinary tract infection 853 160

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Genital Neoplasms, Male? (19)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer. Future oncology (London, England) 2023 Yes
High Risk of Proximal and Local Neoplasms in 2206 Patients With Anogenital Extramammary Paget's Disease. Diseases of the colon and rectum 2019 Yes
Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy. European journal of cancer (Oxford, England : 1990) 2010 Yes
Merck hopes to extend gardasil vaccine to men. Journal of the National Cancer Institute 2009 Yes
Pathophysiology of cell phone radiation: oxidative stress and carcinogenesis with focus on male reproductive system. Reproductive biology and endocrinology : RB&E 2009 Yes

Showing 5 of 19 publications.

Start your 14-day trial Email me all 19 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages